---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-070509"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T12:05:17.531636+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics CFO Jason Amello resigns; Charles Schoch appointed interim CFO

## Summary
- Jason Amello resigned as CFO, principal financial and accounting officer, effective January 12, 2024, to pursue another opportunity.
- Resignation not due to any disagreement with auditors or company on operations, policies, or financial disclosures.
- Charles Schoch, VP of Finance and Corporate Controller, will serve as Interim CFO while a permanent replacement is sought.
- Amello will remain as an advisor to support transition of responsibilities.

## SEC filing metadata
- accession: 0000950170-23-070509
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017023070509/0000950170-23-070509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017023070509/cadl-20231211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-070509
- JSON: https://secwatch.observer/filing/0000950170-23-070509.json
- Plain text: https://secwatch.observer/filing/0000950170-23-070509.txt

## Key facts
- Executive change
  Charles Schoch was appointed as Interim Chief Financial Officer at Candel Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: Effective upon Mr. Amello’s cessation of service as Chief Financial Officer, the Company intends to appoint Charles Schoch, the Company’s current Vice President of Finance and Corporate Controller, as the Company’s Interim Chief Financial Officer, principal financial and principal accounting officer while the Company engages in a search for a permanent replacement for Mr. Amello.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017023070509/0000950170-23-070509-index.htm
- Executive change
  Jason A. Amello resigned as Chief Financial Officer at Candel Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On December 11, 2023, Jason A. Amello notified Candel Therapeutics, Inc. (the “Company”) of his decision to resign from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024, to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017023070509/0000950170-23-070509-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.